Prevail Therapeutics, Inc.
(NASDAQ : PRVL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.96%58.190.0%$1899.37m
REGNRegeneron Pharmaceuticals, Inc. -0.26%597.002.5%$1174.48m
GILDGilead Sciences, Inc. -1.02%76.751.0%$975.82m
AMGNAmgen, Inc. 2.17%225.671.3%$660.44m
NVAXNovavax, Inc. 3.67%46.30102.0%$655.72m
VRTXVertex Pharmaceuticals, Inc. -2.61%265.691.9%$544.78m
ILMNIllumina, Inc. -1.20%354.113.5%$388.06m
BIIBBiogen, Inc. 2.36%306.721.6%$378.26m
SRNESorrento Therapeutics, Inc. 6.74%4.121.8%$269.11m
ALXNAlexion Pharmaceuticals, Inc. 1.35%115.212.0%$241.70m
SGENSeattle Genetics, Inc. -1.36%148.396.1%$223.95m
AAgilent Technologies, Inc. -0.83%90.381.6%$215.81m
BMRNBioMarin Pharmaceutical, Inc. -1.59%105.804.3%$184.97m
SRPTSarepta Therapeutics, Inc. 2.06%147.9913.9%$156.63m
INCYIncyte Corp. -0.31%93.512.5%$153.41m

Company Profile

Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.